Trial Profile

A Phase I Study of DN1406131 in Healthy Adults

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DN-1406131 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Jiangxi Qingfeng Pharmaceutical

Most Recent Events

31 Jul 2019 Status changed from not yet recruiting to recruiting.
06 Sep 2018 According to Shanghai De Novo Pharmatech media release, the U.S. Food and Drug Adminiatrstion (FDA)'s approval of DN1406131's Investigational New Drug (IND) application in Jan 2018, Shanghai De Novo pharmatech Co., Ltd has received Clinical Trial Application (CTA) approval on May 29, 2018 from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with DN1406131.
28 Aug 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com